elacestrant
elacestrant: sourced relationships with 1 company · 15 clinical trials tracked.
elacestrant evidence translation
What we can confirm
15 tracked trials
What it means
What to watch
Prepared research question
How could elacestrant → RDUS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Radius Health, Inc. (RDUS) ER+/HER2- advanced or metastatic breast cancer | Phase 3 |
Clinical Trial Registry Records (15)showing 10 most recent
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Primary endpoint: Proportion of patients progression-free
A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas
Primary endpoint: Objective Response Rate (ORR)
A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)
Primary endpoint: Progression Free Survival (PFS) in ESR1 mutant population
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Primary endpoint: Recommended phase II dose (RP2D)
A Single Arm Phase II Trial of Circulating Tumor DNA-guided Adjuvant Therapy With Elacestrant in Adults With Hormone Receptor Positive HER2 Negative Breast Cancers at Risk for Late Recurrence (CATE)
Primary endpoint: Assessing Elacestrant's Impact on ctDNA Clearance in ER+HER2- Breast Cancer Patients
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors
Primary endpoint: To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).
Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer
Primary endpoint: Rate of Successful Completion
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
Primary endpoint: Invasive Breast Cancer-Free Survival (IBCFS)
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Primary endpoint: Distant metastasis free survival (DMFS)
Frequently asked questions
Which companies have sourced relationships with elacestrant?
elacestrant has dated SEC/FDA relationship records for Radius Health, Inc..
How many clinical trials involve elacestrant?
BioSniper tracks 15 clinical trials involving elacestrant.